Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

18
Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

TAGS:

description

Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies. Statin Intolerance. PROVE-IT TIMI 22. Familial Hypercholesterolemia. Estimated Rates of FH Diagnoses. LDL Hypothesis. Impact of PCSK9 on LDL Receptor Expression. PCSK9 Inhibitors. Abbreviations. Abbreviations (cont). - PowerPoint PPT Presentation

Transcript of Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

Page 1: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

Cardiovascular Risk Management in Dyslipidemia: Clinical

Controversies

Page 2: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

Statin Intolerance

Page 3: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

PROVE-IT TIMI 22

Page 4: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

Familial Hypercholesterolemia

Page 5: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

Estimated Rates of FH Diagnoses

Page 6: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

LDL Hypothesis

Page 7: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

Impact of PCSK9 on LDL Receptor Expression

Page 8: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

PCSK9 Inhibitors

Page 9: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies
Page 10: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies
Page 11: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies
Page 12: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies
Page 13: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies
Page 14: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies
Page 15: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies
Page 16: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

Abbreviations

Page 17: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

Abbreviations (cont)

Page 18: Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

References


Postprandial dyslipidemia: pathophysiology and cardiovascular disease ... · Postprandial dyslipidemia: pathophysiology and cardiovascular disease risk assessment. Victoria Higgins.

Postprandial dyslipidemia: pathophysiology and cardiovascular disease ... · Postprandial dyslipidemia: pathophysiology and cardiovascular disease risk assessment. Victoria Higgins.

Dyslipidemia and Cardiovascular Risk: Lipid Ratios as Risk Factors for Cardiovascular Disease

Dyslipidemia and Cardiovascular Risk: Lipid Ratios as Risk Factors for Cardiovascular Disease

The Role of Nutraceutical Supplements in the …...2/8/2016 1 The Role of Nutraceutical Supplements in the Treatment of Dyslipidemia and Dyslipidemia-induced Vascular Disease CARDIOVASCULAR

The Role of Nutraceutical Supplements in the …...2/8/2016 1 The Role of Nutraceutical Supplements in the Treatment of Dyslipidemia and Dyslipidemia-induced Vascular Disease CARDIOVASCULAR

Cardiovascular Risk and dyslipidemia Dr Stéphane De Wit St Pierre Hospital - Brussels.

Cardiovascular Risk and dyslipidemia Dr Stéphane De Wit St Pierre Hospital - Brussels.

Current Controversies in Dyslipidemia Management:

Current Controversies in Dyslipidemia Management:

Dyslipidemia and Prevention of Cardiovascular Disease

Dyslipidemia and Prevention of Cardiovascular Disease

2012 Update of the Canadian Cardiovascular Society ... · 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia ... (CKD).4

2012 Update of the Canadian Cardiovascular Society ... · 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia ... (CKD).4

The management of Dyslipidemia for Cardiovascular Risk ... · Department of Veterans affairs Department of Defense VA/DoD Clinical Practice Guideline for The management of Dyslipidemia

The management of Dyslipidemia for Cardiovascular Risk ... · Department of Veterans affairs Department of Defense VA/DoD Clinical Practice Guideline for The management of Dyslipidemia

Dyslipidemia and Cardiovascular Risk Reduction: An Evidence-Based Review Peter P. Tóth, MD, PhD Clinical Associate Professor Department of Family and Community.

Dyslipidemia and Cardiovascular Risk Reduction: An Evidence-Based Review Peter P. Tóth, MD, PhD Clinical Associate Professor Department of Family and Community.

HIV, Dyslipidemia, and CVD Risk - Vanderbilt … Dyslipidemia, and CVD Risk Sergio Fazio, MD, PhD Cornelius Vanderbilt Chair of Cardiovascular Medicine Professor of Medicine, Pathology,

HIV, Dyslipidemia, and CVD Risk - Vanderbilt … Dyslipidemia, and CVD Risk Sergio Fazio, MD, PhD Cornelius Vanderbilt Chair of Cardiovascular Medicine Professor of Medicine, Pathology,

Cardiovascular Disease Dyslipidemia: Non-Pharmacologic Treatment · Cardiovascular Disease Dyslipidemia: Non-Pharmacologic Treatment Mark C. Houston, M.D., M.S. ABAARM, FACP, FACN,

Cardiovascular Disease Dyslipidemia: Non-Pharmacologic Treatment · Cardiovascular Disease Dyslipidemia: Non-Pharmacologic Treatment Mark C. Houston, M.D., M.S. ABAARM, FACP, FACN,

Dyslipidemia and Cardiovascular Risk Reduction: An Evidence-Based Review Robert M. Guthrie, MD Professor of Emergency Medicine Professor of Internal Medicine.

Dyslipidemia and Cardiovascular Risk Reduction: An Evidence-Based Review Robert M. Guthrie, MD Professor of Emergency Medicine Professor of Internal Medicine.

Introduction Approximately 1 in 3 of adults, have cardiovascular disease vascular/metabolic risk factors such as hypertension, dyslipidemia, and diabetes;

Introduction Approximately 1 in 3 of adults, have cardiovascular disease vascular/metabolic risk factors such as hypertension, dyslipidemia, and diabetes;

Chapter 4 Abstract Cancer Associated Dyslipidemia€¦ · Advances in Dyslipidemia Advances in Dyslipidemia Aberrant blood lipid profiles/dyslipidemia has long been considered as

Chapter 4 Abstract Cancer Associated Dyslipidemia€¦ · Advances in Dyslipidemia Advances in Dyslipidemia Aberrant blood lipid profiles/dyslipidemia has long been considered as

Risk Assessment of Cardiovascular Diseases and Dyslipidemia Done by: Faisal AlFayyadh Nawaf AlAmiri.

Risk Assessment of Cardiovascular Diseases and Dyslipidemia Done by: Faisal AlFayyadh Nawaf AlAmiri.

Guidelines for Management of Dyslipidemiasyllabus.aace.com/2018/PCP/Cerritos/presentations/Guerin... · AACE Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular

Guidelines for Management of Dyslipidemiasyllabus.aace.com/2018/PCP/Cerritos/presentations/Guerin... · AACE Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular

Controversies & Advances in the Treatment of Cardiovascular Disease

Controversies & Advances in the Treatment of Cardiovascular Disease

Dyslipidemia. Topics to be covered today What is dyslipidemia? Classification of dyslipidemia Secondary causes of lipoprotein abnormalities Rationale.

Dyslipidemia. Topics to be covered today What is dyslipidemia? Classification of dyslipidemia Secondary causes of lipoprotein abnormalities Rationale.

DIABETIC DYSLIPIDEMIA A MAJOR RISK FACTOR IN CARDIOVASCULAR DISEASES Banciu Andreea Maria Grigore Mihai Associated Professor: Minerva Boitan 1.

DIABETIC DYSLIPIDEMIA A MAJOR RISK FACTOR IN CARDIOVASCULAR DISEASES Banciu Andreea Maria Grigore Mihai Associated Professor: Minerva Boitan 1.

Dyslipidemia: Managing a Key Cardiovascular Risk Factor AIMGP Clinic Seminar Updated by R. Cavalcanti Sep 2007.

Dyslipidemia: Managing a Key Cardiovascular Risk Factor AIMGP Clinic Seminar Updated by R. Cavalcanti Sep 2007.